Table 1.
The timing of the circulating cardiac biomarker rise in response to cancer treatment. Summary of human trials dealing with cardiotoxicity and circulating cardiac biomarkers in the last 5 years
| Cancer type | Mean ANT exposure | Reported CTxN(%) | Biomarker | Reported time of significant elevation (days) |
|---|---|---|---|---|
| Breast, leukemia, lymphoma [30] | 240–360 mg/m2 DOX | 5 (9.6) | hs-cTnI | 21 |
| Breast, NHL [31] | 240–402 mg/m2 DOX | 0 | hs-cTnT | 91–154 |
| Breast [32] | Not stated | 3 (0.6) + 31 (7) | hs-cTnT, hs-cTnI | 90 |
| Lymphoma [33] | 496.2 ± 89.4 mg/m2–707.9 ± 83.0 mg/m2 DOX | 5 (6) | hs-cTnT | 42–84 |
| Breast [34] | 240 mg/m2 DOX | 23 (24) | cTnI | 90 |
| Breast [35] | 300–400 mg/m2 EPI | 4 (10) | hs-cTnT | 90 |
| Breast [36] | 240 mg/m2 DOX | Not stated | hs-cTnT | 2–22 |
| Breast, NHL, leukemia [37•] | 240 mg/m2 DOX, 360 mg/m2 EPI | 3 (1) | cTn | 25 |
| Breast [38•] | 240–400 mg/m2 EPI | 1 | hs-cTnI, hs-cTnT | 77–87 |
| Breast [39•] | 240 mg/m2 DOX | 27 (14) | hs-cTnI | 84 |
| Lymphoma, sacoma, breast [40] | 308 ± 111 mg/m2 (not specified) | 11 (10) | NTproBNP | 108 |
| Breast [41] | 0 | 4 (9) | NTproBNP | 30–180 |
| Breast [42] | Not stated | 45 (33) | NTproBNP | Not stated |
| Breast [43] | 240 mg/m2 | 57 (22%) | hs-cTnT, NT-proBNP | 0–180 (for both) |
| Lymphoma, myeloma [44] | 0 | 12% | hs-cTnT | 16 |
ANT anthracyclines, DOX doxorubicine, EPI epirubicine, CTx cardiotoxicity, NHL non-Hodgkin lymphoma, hs-cTnI high sensitive cardiac troponin I, hs-cTnT high sensitive cardiac troponin T